Genmark Diagnostics Inc (NASDAQ:GNMK): Negative Stock Sentiment

June 16, 2018 - By Nellie Frank

Sentiment for Genmark Diagnostics Inc (NASDAQ:GNMK)

Genmark Diagnostics Inc (NASDAQ:GNMK) institutional sentiment decreased to 1.12 in 2018 Q1. Its down -0.14, from 1.26 in 2017Q4. The ratio dropped, as 38 investment managers opened new and increased equity positions, while 34 cut down and sold their positions in Genmark Diagnostics Inc. The investment managers in our partner’s database now hold: 50.51 million shares, down from 53.33 million shares in 2017Q4. Also, the number of investment managers holding Genmark Diagnostics Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 9 Reduced: 25 Increased: 25 New Position: 13.

GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. The company has market cap of $403.40 million. The firm provides XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It currently has negative earnings. It offers diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, warfarin sensitivity test, and thrombophilia risk test, as well as HCV genotyping test and associated custom manufactured reagents, and 2C19 genotyping test.

The stock decreased 0.41% or $0.03 during the last trading session, reaching $7.28. About 352,918 shares traded or 22.89% up from the average. GenMark Diagnostics, Inc. (NASDAQ:GNMK) has declined 45.92% since June 16, 2017 and is downtrending. It has underperformed by 58.49% the S&P500.

Analysts await GenMark Diagnostics, Inc. (NASDAQ:GNMK) to report earnings on August, 7. They expect $-0.21 earnings per share, up 43.24 % or $0.16 from last year’s $-0.37 per share. After $-0.21 actual earnings per share reported by GenMark Diagnostics, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Cadian Capital Management Lp holds 1.48% of its portfolio in GenMark Diagnostics, Inc. for 5.04 million shares. Needham Investment Management Llc owns 180,000 shares or 0.28% of their US portfolio. Moreover, Private Wealth Partners Llc has 0.28% invested in the company for 300,000 shares. The Pennsylvania-based Penn Capital Management Co Inc has invested 0.18% in the stock. Hightower Advisors Llc, a Illinois-based fund reported 2.37 million shares.

Since January 1, 0001, it had 1 insider buy, and 50 insider sales for $736,681 activity.

GenMark Diagnostics, Inc. (NASDAQ:GNMK) Ratings Coverage

Ratings analysis reveals 100% of GenMark’s analysts are positive. Out of 2 Wall Street analysts rating GenMark, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $8 while the high is $11.0. The stock’s average target of $9.50 is 30.49% above today’s ($7.28) share price. GNMK was included in 3 notes of analysts from January 19, 2018. The firm has “Buy” rating given on Wednesday, February 28 by Canaccord Genuity. Needham maintained the stock with “Buy” rating in Wednesday, May 2 report. The firm has “Buy” rating by Needham given on Friday, January 19.

Another recent and important GenMark Diagnostics, Inc. (NASDAQ:GNMK) news was published by Nasdaq.com which published an article titled: “GenMark Diagnostics to Present at the William Blair 38th Annual Growth Stock Conference” on June 06, 2018.

GenMark Diagnostics, Inc. (NASDAQ:GNMK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: